Technical and clinical considerations for electroencephalography-based biomarkers for major depressive disorder.

Autor: Simmatis L; Faculty of Medicine, University of Toronto, Toronto, ON, Canada.; Cove Neurosciences Inc., Toronto, ON, Canada., Russo EE; Faculty of Medicine, University of Toronto, Toronto, ON, Canada.; Cove Neurosciences Inc., Toronto, ON, Canada., Geraci J; Cove Neurosciences Inc., Toronto, ON, Canada.; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada., Harmsen IE; Faculty of Medicine, University of Toronto, Toronto, ON, Canada.; Cove Neurosciences Inc., Toronto, ON, Canada., Samuel N; Faculty of Medicine, University of Toronto, Toronto, ON, Canada. nardin.samuel@mail.utoronto.ca.; Cove Neurosciences Inc., Toronto, ON, Canada. nardin.samuel@mail.utoronto.ca.
Jazyk: angličtina
Zdroj: Npj mental health research [Npj Ment Health Res] 2023 Oct 25; Vol. 2 (1), pp. 18. Date of Electronic Publication: 2023 Oct 25.
DOI: 10.1038/s44184-023-00038-7
Abstrakt: Major depressive disorder (MDD) is a prevalent and debilitating psychiatric disease that leads to substantial loss of quality of life. There has been little progress in developing new MDD therapeutics due to a poor understanding of disease heterogeneity and individuals' responses to treatments. Electroencephalography (EEG) is poised to improve this, owing to the ease of large-scale data collection and the advancement of computational methods to address artifacts. This review summarizes the viability of EEG for developing brain-based biomarkers in MDD. We examine the properties of well-established EEG preprocessing pipelines and consider factors leading to the discovery of sensitive and reliable biomarkers.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: